Skip to main content
. Author manuscript; available in PMC: 2018 Aug 20.
Published in final edited form as: Sci Transl Med. 2017 Sep 20;9(408):eaan4220. doi: 10.1126/scitranslmed.aan4220

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors.

Fig. 8.

B16-F10.9-OVA-CD155 tumors were implanted subcutaneously, and when the tumor volume reached ~100 mm3, they were injected with DMEM (control) or mRIPO. Tumors were harvested after injection as indicated, digested to single cell suspensions, and analyzed by flow cytometry. (A) Analysis of percentage of CD45.2+ immune cells in the tumor after DMEM (control) or mRIPO treatment. Each bar represents 3 mice analyzed individually. (B) Cytokine concentrations in tumor homogenates. (C to E) Analysis of tumor-infiltrating neutrophils (C), DCs (D), and T cells (E) at the indicated days after mRIPO injection. (F) Longitudinal analysis of neutrophil, DC, CD4+ T cell, and CD8+ T cell infiltration is depicted as a percentage of total live cells in the tumor. Each bar represents 3 mice analyzed individually. Error bars represent SEM. The flow cytometry gating strategy is shown in fig. S9 and S10.